Pinned Tweet
Yesterday, dozens of rare disease patients, families & developers each spoke for 2.5 minutes across a 3-hour FDA public comment session. Every single story was heartbreaking and profoundly earnest. May the FDA truly become an agency that delivers real hope and a future to all. 🙏
Rare disease patients & families delivered a unified message at the FDA Framework meeting: traditional placebo trials are impossible for small populations.
They demanded formal regulatory acceptance of standardized natural history registries as external controls. $QURE (1/5)
1
699
1/2 Per UBS BioPharma Day 1 takeaways, $QURE CEO Matt Kapusta focused on AMT-130's May 1, 2027 PDUFA, expected AdCom, and launch readiness.
Management reiterated an AdCom is the base case for a first disease-modifying, one-time HD gene therapy (~March 2027 expected).
1/5 A new peer-reviewed review in Int. J. Mol. Sci. (Nov 17, 2026) by Italian researchers (no COI) surveys 5 Huntington's disease strategies—highlighting $QURE's Sept 2026 marketing submissions for AMT-130 alongside the discontinuation of Roche's tominersen.
1
16
1,494
4/5 The authors urge caution on $QURE's interim findings:
small sample size, ENROLL-HD external controls with 53% missingness at 48 mos, and 5 resolved treatment-related CNS inflammation SAEs—noting a controlled confirmatory trial is required to confirm benefit.
1
3
513
5/5 Across the 5 strategies reviewed, genome editing, proteostasis, and most CAG-expansion programs remain preclinical, while downstream trials largely missed endpoints.
Combining $QURE -style RNAi HTT lowering with expansion suppression showed synergy in mice.
3
592
1/4 "Up to 80%" huntingtin reduction in primates? Cool headline—now show the average, sample size, and stats.
Zero humans have been dosed with Arexera's ATL-101 yet, and its Phase 1 is starting in... China. Meanwhile, $QURE is already in FDA Priority Review.
Replying to @Master_SeaSeo
3/4 Good luck pitching standalone China Phase 1 data to the FDA right now, too—especially after U.S. lawmakers urged rejecting uninspected China trial data and the FDA called for tighter foreign-site oversight.
Another hurdle $QURE doesn't have.
2
5
568
1/3 In its Nov 16 Modeling Analysis Plan for $QURE's AMT-130 in Huntington's disease,
ICER set a $2.6M placeholder price—the midpoint between Leerink's $1.7M estimate and IPD Analytics' $2.5M–$3.5M range (plus $24,138.83 administration cost).
HOWEVER, 👇👇👇
2
14
1,587
2/3 For historical context on $QURE's prior gene therapy, Hemgenix (etranacogene dezaparvovec for Hemophilia B, commercialized with CSL Behring):
ICER's Dec 2022 Health Benefit Price Benchmark was $2.93M–$2.96M,
✅while actual US launch WAC was set at $3.5M.‼️
1
7
510
3/3 ICER benchmarks are non-binding. Key upcoming ICER dates for $QURE's AMT-130:
• Jan 19, 2027: Draft Evidence Report (first HBPB range)
• Mar 25, 2027: Midwest CEPAC public meeting
• Apr 29, 2027: Final Evidence Report (ahead of May 1, 2027 PDUFA)
7
458
1/4 $QURE has posted 4 US Field "Patient Navigator" openings covering Central, East, Mid-West, and West territories (45 states total).
The remote roles report to the Director, Patient Services, with a listed base salary range of $116,000–$150,000.
3/4 Key $QURE responsibilities focus on access & logistics:
Conducting benefits investigations, supporting prior authorizations & appeals, identifying co-pay and travel/lodging assistance, and coordinating with specialty distribution (buy & bill) and specialty pharmacies.
1
8
385
4/4 Internally, $QURE Patient Navigators collaborate with treatment centers, Account Management, and Field Reimbursement Managers (FRMs) on scheduling and coverage resolution.
Qualifications require 3–5 yrs of experience (rare disease or gene therapy strongly preferred).
8
335
1/4 Wells Fargo reiterates Overweight ($75 PT) on $QURE:
Optimistic on AMT-130 FDA approval (May 1, 2027 PDUFA) and highlights near-term CBER rare disease decisions (e.g., deramiocel) as an asymmetric positive readthrough.
1
13
1,139
3/4 On $QURE commercial readiness:
>15 treatment centers expected at launch (25–30 possible), prioritizing high-capacity sites (~2 procedures/week) first, with payer talks underway and the core commercial team in place by early '27.
1
8
497
4/4 Valuation & catalysts for $QURE:
Wells Fargo's $75 Base Case uses a conservative 10% discount rate & 0% terminal growth, with $100 Upside on strong AMT-130 launch + 1H27 readouts for AMT-260 (MTLE) and AMT-191 (Fabry).
























